Giorgio G Fumagalli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7509969/publications.pdf

Version: 2024-02-01

90 papers	3,340 citations	186265 28 h-index	161849 54 g-index
91 all docs	91 docs citations	91 times ranked	4853 citing authors

#	Article	IF	Citations
1	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Applied Neuropsychology Adult, 2022, 29, 112-119.	1.2	18
2	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	7.6	27
3	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp>: A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	5.3	21
4	Caregiver Tele-Assistance for Reduction of Emotional Distress During the COVID-19 Pandemic. Psychological Support to Caregivers of People with Dementia: The Italian Experience. Journal of Alzheimer's Disease, 2022, 85, 1045-1052.	2.6	7
5	Association of Superficial White Matter Alterations with Cerebrospinal Fluid Biomarkers and Cognitive Decline in Neurodegenerative Dementia. Journal of Alzheimer's Disease, 2022, 85, 431-442.	2.6	2
6	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimer's Research and Therapy, 2022, 14, 10.	6.2	4
7	Unravelling the Association Between Amyloid-PET and Cerebrospinal Fluid Biomarkers in the Alzheimerâ€™s Disease Spectrum: Who Really Deserves an A+?. Journal of Alzheimer's Disease, 2022, 85, 1009-1020.	2.6	5
8	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	2.4	2
9	Amyloid PET imaging and dementias: potential applications in detecting and quantifying early white matter damage. Alzheimer's Research and Therapy, 2022, 14, 33.	6.2	9
10	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.8	24
11	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	3.1	1
12	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	3.7	1
13	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.8	36
14	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12185.	2.4	11
15	Facing the digital divide into a dementia clinic during COVID-19 pandemic: caregiver age matters. Neurological Sciences, 2021, 42, 1247-1251.	1.9	47
16	Detection of the SQSTM1 Mutation in a Patient with Early-Onset Hippocampal Amnestic Syndrome. Journal of Alzheimer's Disease, 2021, 79, 477-481.	2.6	2
17	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	5.9	42
18	Diogenes syndrome in dementia: a case report. BJPsych Open, 2021, 7, e43.	0.7	0

#	Article	IF	Citations
19	Analysis of C9orf72 Intermediate Alleles in a Retrospective Cohort of Neurological Patients: Risk Factors for Alzheimerâ€™s Disease?. Journal of Alzheimer's Disease, 2021, 81, 1445-1451.	2.6	6
20	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	6.2	12
21	Niemann-Pick Type C 1 (NPC1) and NPC2 Gene Variability in Demented Patients with Evidence of Brain Amyloid Deposition. Journal of Alzheimer's Disease, 2021, 83, 1313-1323.	2.6	5
22	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	2.7	28
23	Disease-related cortical thinning in presymptomatic granulin mutation carriers. NeuroImage: Clinical, 2021, 29, 102540.	2.7	8
24	Unravelling the association between amyloid-pet and CSF biomarkers: Who really deserves an Aâ€¯+?. Journal of the Neurological Sciences, 2021, 429, 117853.	0.6	0
25	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	10.8	9
26	Low CSF Î²-amyloid levels predict early regional grey matter atrophy in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 39, 101899.	2.0	5
27	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
28	Parieto-occipital sulcus widening differentiates posterior cortical atrophy from typical Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102453.	2.7	11
29	Phenotypic heterogeneity of the rare R377W PSEN1 mutation: Lateâ€onset presentation with mixed Alzheimerâ€™s and frontotemporal dementia features. Alzheimer's and Dementia, 2020, 16, e042581.	0.8	0
30	Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression. Multiple Sclerosis Journal, 2020, 26, 1268-1269.	3.0	35
31	MiRNA Profiling in Plasma Neural-Derived Small Extracellular Vesicles from Patients with Alzheimerâ€™s Disease. Cells, 2020, 9, 1443.	4.1	60
32	Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study. Neurological Sciences, 2020, 41, 3175-3183.	1.9	16
33	Crossing Borders Between Frontotemporal Dementia and Psychiatric Disorders: An Updated Overview. Journal of Alzheimer's Disease, 2020, 75, 661-673.	2.6	3
34	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. Annals of Neurology, 2020, 88, 113-122.	5.3	19
35	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	2.4	26
36	CSF Î²-amyloid predicts prognosis in patients with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1223-1231.	3.0	19

#	Article	IF	Citations
37	Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes. Alzheimer's Research and Therapy, 2019, 11, 84.	6.2	28
38	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	10.2	128
39	Monozygotic Twins with Frontotemporal Dementia Due To Thr272fs GRN Mutation Discordant for Age At Onset. Journal of Alzheimer's Disease, 2019, 67, 1173-1179.	2.6	4
40	Inflammatory expression profile in peripheral blood mononuclear cells from patients with Nasu-Hakola Disease. Cytokine, 2019, 116, 115-119.	3.2	6
41	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. NeuroImage, 2019, 189, 645-654.	4.2	33
42	Cerebrospinal Fluid Level of Aquaporin4: A New Window on Glymphatic System Involvement in Neurodegenerative Disease?. Journal of Alzheimer's Disease, 2019, 69, 663-669.	2.6	21
43	Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. Brain, 2019, 142, 1108-1120.	7.6	41
44	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	2.7	27
45	Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. NeuroImage, 2019, 188, 282-290.	4.2	16
46	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiology of Aging, 2019, 77, 169-177.	3.1	47
47	Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF Î²-amyloid levels and brain volumes. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 280-287.	6.4	28
48	The loss of macular ganglion cells begins from the early stages of disease and correlates with brain atrophy in multiple sclerosis patients. Multiple Sclerosis Journal, 2019, 25, 31-38.	3.0	39
49	Drug Prescription and Delirium in Older Inpatients. Journal of Clinical Psychiatry, 2019, 80, .	2.2	16
50	Profiling of Specific Gene Expression Pathways in Peripheral Cells from Prodromal Alzheimerâ€™s Disease Patients. Journal of Alzheimer's Disease, 2018, 61, 1289-1294.	2.6	2
51	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
52	Diagnosis of Frontotemporal Dementia. , 2018, , 113-121.		0
53	Comparison of arterial spin labeling registration strategies in the multiâ€center GENetic frontotemporal dementia initiative (GENFI). Journal of Magnetic Resonance Imaging, 2018, 47, 131-140.	3.4	41
54	CSF Î²-amyloid and white matter damage: a new perspective on Alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 352-357.	1.9	36

#	Article	IF	Citations
55	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiology of Aging, 2018, 62, 191-196.	3.1	151
56	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiology of Aging, 2018, 62, 245.e9-245.e12.	3.1	40
57	Behavioral and Neurophysiological Effects of Transcranial Direct Current Stimulation (tDCS) in Fronto-Temporal Dementia. Frontiers in Behavioral Neuroscience, 2018, 12, 235.	2.0	19
58	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nature Communications, 2018, 9, 4273.	12.8	263
59	Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales. Alzheimer's Research and Therapy, 2018, 10, 46.	6.2	34
60	Presymptomatic white matter integrity loss in familial frontotemporal dementia in the <scp>GENFI</scp> cohort: A crossâ€sectional diffusion tensor imaging study. Annals of Clinical and Translational Neurology, 2018, 5, 1025-1036.	3.7	39
61	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. Brain, 2017, 140, 1784-1791.	7.6	55
62	White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort. NeuroImage: Clinical, 2017, 15, 171-180.	2.7	63
63	Evidence of CNS Î²-amyloid deposition in Nasu-Hakola disease due to the TREM2 Q33X mutation. Neurology, 2017, 89, 2503-2505.	1.1	26
64	Word and Picture Version of the Free and Cued Selective Reminding Test (FCSRT): Is There Any Difference?. Journal of Alzheimer's Disease, 2017, 61, 47-52.	2.6	8
65	CSF Î²-amyloid as a putative biomarker of disease progression in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1085-1091.	3.0	33
66	The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design. Neurological Sciences, 2017, 38, 83-91.	1.9	11
67	Alzheimerâ€™s Disease Diagnosis: Discrepancy between Clinical, Neuroimaging, and Cerebrospinal Fluid Biomarkers Criteria in an Italian Cohort of Geriatric Outpatients: A Retrospective Cross-sectional Study. Frontiers in Medicine, 2017, 4, 203.	2.6	8
68	PRNP P39L Variant is a Rare Cause ofÂFrontotemporal Dementia in Italian Population. Journal of Alzheimer's Disease, 2016, 50, 353-357.	2.6	15
69	P1â€025: Cerebral Perfusion as an Imaging Biomarker of Presymptomatic Genetic Frontotemporal Dementia: Preliminary Results from the Genetic Frontotemporal Dementia Initiative (GENFI). Alzheimer's and Dementia, 2016, 12, P409.	0.8	0
70	MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. Brain, 2016, 139, 1211-1225.	7.6	174
71	O4-08-06: Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning. , 2015, 11, P289-P289.		0
72	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurology, The, 2015, 14, 253-262.	10.2	432

#	Article	IF	Citations
73	Inflammatory molecules in Frontotemporal Dementia: Cerebrospinal fluid signature of progranulin mutation carriers. Brain, Behavior, and Immunity, 2015, 49, 182-187.	4.1	51
74	Profiling of Ubiquitination Pathway Genes in Peripheral Cells from Patients with Frontotemporal Dementia due to C9ORF72 and GRN Mutations. International Journal of Molecular Sciences, 2015, 16, 1385-1394.	4.1	14
75	Usefulness of Multi-Parametric MRI for the Investigation of Posterior Cortical Atrophy. PLoS ONE, 2015, 10, e0140639.	2.5	4
76	Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy. Immunotherapy, 2014, 6, 23-28.	2.0	3
77	Circulating miRNAs as Potential Biomarkers in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 1261-1267.	2.6	188
78	Autosomal Dominant Frontotemporal Lobar Degeneration Due to the C9ORF72 Hexanucleotide Repeat Expansion: Late-Onset Psychotic Clinical Presentation. Biological Psychiatry, 2013, 74, 384-391.	1.3	105
79	A 66-year-old patient with vanishing white matter disease due to the p.Ala87Val EIF2B3 mutation. Neurology, 2012, 79, 2077-2078.	1.1	16
80	Early Onset Behavioral Variant Frontotemporal Dementia due to the C9ORF72 Hexanucleotide Repeat Expansion: Psychiatric Clinical Presentations. Journal of Alzheimer's Disease, 2012, 31, 447-452.	2.6	60
81	Sciatic endometriosis presenting as periodic (catamenial) sciatic radiculopathy. Journal of Neurology, 2012, 259, 1470-1471.	3.6	12
82	BAG1 is a Protective Factor for Sporadic Frontotemporal Lobar Degeneration but not for Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 23, 701-707.	2.6	12
83	Phenotypic Heterogeneity of the GRN Asp22fs Mutation in a Large Italian Kindred. Journal of Alzheimer's Disease, 2011, 24, 253-259.	2.6	62
84	A Novel MAPT Mutation Associated with the Clinical Phenotype of Progressive Nonfluent Aphasia. Journal of Alzheimer's Disease, 2011, 26, 19-26.	2.6	28
85	Cell-dependent kinase inhibitor 2A and 2B genetic variability in patients with Alzheimerâ€™s disease. Journal of Neurology, 2011, 258, 704-705.	3.6	1
86	Role of hnRNP-A1 and miR-590-3p in Neuronal Death: Genetics and Expression Analysis in Patients with Alzheimer Disease and Frontotemporal Lobar Degeneration. Rejuvenation Research, 2011, 14, 275-281.	1.8	57
87	Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males. Genes and Immunity, 2010, 11, 497-503.	4.1	17
88	Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes. Neuroscience Letters, 2010, 469, 234-236.	2.1	24
89	Is KIF24 a genetic risk factor for Frontotemporal Lobar Degeneration?. Neuroscience Letters, 2010, 482, 240-244.	2.1	9
90	Teaching Neuroimage: Crowned Dens Syndrome, an Acute Attack of Calcium Pyrophosphate Deposition Disease Mimicking Acute Meningitis. Neurology, 0, , 10.1212/WNL.0000000000200949.	1.1	0